FDA Approves COSENTYX — Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals received FDA approval for Secukinumab (Cosentyx) on Jan. 21, 2015, a strategic milestone expected to bolster the company’s portfolio in the autoimmune therapeutic market and drive future revenue growth.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day